Virometix
Schlieren
About Virometix
Virometix is a privately held biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and chronic human diseases. In an increasingly global world there is a considerable medical need for vaccines to combat infectious as well as a number of chronic human diseases. Fast growing demands, health threats from newly arising complex viral and bacterial pathogens and increasingly stringent requirements for stability, safety and tolerability require new approaches to tackling current and future challenges. Rational molecular design, chemical synthesis and Virometix' proprietary Synthetic Virus-Like Particle platform technology allow for the rapid production and optimization of vaccine candidates with superior properties in terms of safety, efficacy and stability.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $10K – $50K
- Total funding: $29.3M
- Last round: Undisclosed (Nov 2025)
- Website: virometix.com
- Phone: +41 (0) 43 433 86 60
Industries & Categories
Biotechnology, Health Care, Medical
Canonical: https://fsome.com/organization/virometix-16221 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.